FK1706 enhances the recovery of erectile function following bilateral cavernous nerve crush injury in the rat

被引:32
作者
Bella, Anthony J.
Hayashi, Narihiko
Carrion, Rafael E.
Price, Raymond
Lue, Tom F.
机构
[1] Univ Calif San Francisco, Div Urol, San Francisco, CA 94143 USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[3] Univ S Florida, Dept Urol, Tampa, FL USA
[4] Astellas Pharma Inc, Pharmacol Res Lab, Tsukuba, Japan
关键词
neurogenic impotence; FK1706; FK506; immunophilin ligand; animal model; erectile dysfunction;
D O I
10.1111/j.1743-6109.2007.00438.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction. Advances in neurobiology have led to a surge of clinical interest in the development of protective and regenerative neuromodulatory strategies, as surgical therapies for prostate cancer often result in neuronal damage and debilitating loss of sexual function. Aim. To investigate the dose-dependent efficacy of FK1706, a nonimmunosuppressant immunophilin ligand, for the recovery of erectile function following bilateral cavernous nerve crush injury in the rat. Main Outcome Measures. Recovery of erectile function was assessed by cavernous nerve electrostimulation and reported as maximal increase of intracavernous pressure (ICP) and area under the curve (AUC). Changes in animal weights, percentage completion of treatment course, and survival were compared between groups. Methods. Thirty-five Sprague-Dawley male rats were randomly divided into five equal groups: seven animals received a sham operation, whereas 28 animals underwent bilateral cavernous nerve crush injury, followed by subcutaneous injection of vehicle alone (1.0 mL/kg), or low (0.1 mg/kg), medium (0.32 mg/kg), or high dose (1.0 mg/kg) FK1706 5 days per week for 8 weeks. Results. Erectile dysfunction did not occur in the sham group (mean maximal ICP increase of 100.8 +/- 6.3 cmH(2)O), whereas nerve injury and vehicle treatment produced a significant reduction in ICP response to 34.4 +/- 12.8 cmH(2)O. The mean ICP increase for high-dose FK106 treatment was 73.9 +/- 6.3 cmH(2)O (P < 0.01 vs. vehicle) compared with 58.3 +/- 7.4 cmH(2)O and 56.9 +/- 8.3 for low and medium doses (P > 0.05). Similar stepwise findings were observed using AUC data. No significant maximal aortic blood pressure or weight differences occurred between groups and all animals completed treatment. Conclusion. High-dose subcutaneous FK1706 therapy promoted recovery of erectile function following bilateral cavernous nerve crush injury in the rat. No significant differences between groups were observed for changes in weight, and the 8-week treatment course was completed for all animals.
引用
收藏
页码:341 / 346
页数:6
相关论文
共 25 条
[1]   Erythropoietin promotes the recovery of erectile function following cavernous nerve injury [J].
Allaf, ME ;
Hoke, A ;
Burnett, AL .
JOURNAL OF UROLOGY, 2005, 174 (05) :2060-2064
[2]  
Bella AJ, 2006, J SEX MED, V3, P815, DOI 10.1111/j.1743-6109.2006.00291.x
[3]   The effect of neural embryonic stem cell therapy in a rat model of cavernosal nerve injury [J].
Bochinski, D ;
Lin, GT ;
Nunes, L ;
Carrion, R ;
Rahman, N ;
Lin, CS ;
Lue, TF .
BJU INTERNATIONAL, 2004, 94 (06) :904-909
[4]   Immunophilin ligands promote penile neurogenesis and erection recovery after cavernous nerve injury [J].
Burnett, AL ;
Becker, RE .
JOURNAL OF UROLOGY, 2004, 171 (01) :495-500
[5]   Neuromodulatory therapy to improve erectile function recovery outcomes after pelvic surgery [J].
Burnett, Arthur L. ;
Lue, Tom F. .
JOURNAL OF UROLOGY, 2006, 176 (03) :882-887
[6]   The effect of intracavernosal growth differentiation factor-5 therapy in a rat model of cavernosal nerve injury [J].
Fandel, Thomas M. ;
Bella, Anthony J. ;
Tantiwongse, Kavirach ;
Garcia, Maurice ;
Nunes, Lora ;
Thueroff, Joachim W. ;
Tanagho, Emil A. ;
Pohl, Jens ;
Lue, Tom F. .
BJU INTERNATIONAL, 2006, 98 (03) :632-636
[7]   Non-FK506-binding protein-12 neuroimmunophilin Ligands increase neurite elongation and accelerate nerve regeneration [J].
Gold, BG ;
Armistead, DM ;
Wang, MS .
JOURNAL OF NEUROSCIENCE RESEARCH, 2005, 80 (01) :56-65
[8]   FK506 and a nonimmunosuppressant derivative reduce axonal and myelin damage in experimental autoimmune encephalomyelitis: Neuroimmunophilin ligand-mediated neuroprotection in a model of multiple sclerosis [J].
Gold, BG ;
Voda, J ;
Yu, XL ;
McKeon, G ;
Bourdette, DN .
JOURNAL OF NEUROSCIENCE RESEARCH, 2004, 77 (03) :367-377
[9]   The effect of FK1706 on erectile function following bilateral cavernous nerve crush injury in a rat model [J].
Hayashi, Narihiko ;
Minor, Thomas X. ;
Carrion, Rafael ;
Price, Raymond ;
Nunes, Lora ;
Lue, Tom F. .
JOURNAL OF UROLOGY, 2006, 176 (02) :824-829
[10]   Neuroprotection in the PNS:: Erythropoietin and immunophilin ligands [J].
Höke, A ;
Keswani, SC .
NEUROPROTECTIVE AGENTS, 2005, 1053 :491-501